Patient characteristics
| Parameter . | Patients . | |
|---|---|---|
| Male | 52/105 (49.5) | |
| Female | 53/105 (50.5) | |
| Median age, y (range) | 49 (13–79) | |
| High serum LDH (>250 U/L) | 74/96 (77.1) | |
| High serum B2 microglobulin (>2.5mg/L) | 55/96 (57.3) | |
| ECOG 2 or higher | 52/105 (49.5) | |
| Stage III/IV | 93/105 (88.6) | |
| Extranodal involvement >1 | 50/105 (47.6) | |
| Bone marrow involvement | 13/103 (12.6) | |
| IPI score | ||
| 1 | 13/105 (12.4) | |
| 2 | 26/105 (24.8) | |
| 3 | 37/105 (35.2) | |
| 4, 5 | 29/105 (27.6) | |
| Median chemotherapy cycles, n (range) | 11 (3–22) | |
| B symptoms | 52/105 (49.5) | |
| Hans classifier | ||
| GCB | 31/105 (29.5) | |
| Non-GCB | 74/105 (70.5) | |
| GCB | non-GCB | |
| MYC-break positive | 12/31 (38.7) | 7/74 (9.5) |
| BCL2-break positive | 10/31 (32.2) | 3/74 (4.1) |
| BCL6-break positive | 7/31 (22.6) | 11/74 (14.9) |
| Parameter . | Patients . | |
|---|---|---|
| Male | 52/105 (49.5) | |
| Female | 53/105 (50.5) | |
| Median age, y (range) | 49 (13–79) | |
| High serum LDH (>250 U/L) | 74/96 (77.1) | |
| High serum B2 microglobulin (>2.5mg/L) | 55/96 (57.3) | |
| ECOG 2 or higher | 52/105 (49.5) | |
| Stage III/IV | 93/105 (88.6) | |
| Extranodal involvement >1 | 50/105 (47.6) | |
| Bone marrow involvement | 13/103 (12.6) | |
| IPI score | ||
| 1 | 13/105 (12.4) | |
| 2 | 26/105 (24.8) | |
| 3 | 37/105 (35.2) | |
| 4, 5 | 29/105 (27.6) | |
| Median chemotherapy cycles, n (range) | 11 (3–22) | |
| B symptoms | 52/105 (49.5) | |
| Hans classifier | ||
| GCB | 31/105 (29.5) | |
| Non-GCB | 74/105 (70.5) | |
| GCB | non-GCB | |
| MYC-break positive | 12/31 (38.7) | 7/74 (9.5) |
| BCL2-break positive | 10/31 (32.2) | 3/74 (4.1) |
| BCL6-break positive | 7/31 (22.6) | 11/74 (14.9) |
Data are expressed as the number of patients/number of patients in the study group (percentage of the total group), if not otherwise stated.
LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index.